Aster Capital Management DIFC Ltd Takes $2.06 Million Position in AbbVie Inc. $ABBV

Aster Capital Management DIFC Ltd bought a new position in shares of AbbVie Inc. (NYSE:ABBV) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 8,915 shares of the company’s stock, valued at approximately $2,064,000. AbbVie accounts for about 1.0% of Aster Capital Management DIFC Ltd’s holdings, making the stock its 13th largest holding.

A number of other institutional investors also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of AbbVie during the 2nd quarter worth $4,288,200,000. Laurel Wealth Advisors LLC raised its stake in AbbVie by 18,384.4% in the second quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock valued at $1,059,141,000 after buying an additional 5,675,095 shares in the last quarter. Vanguard Group Inc. raised its stake in AbbVie by 1.9% in the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after buying an additional 3,380,842 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its holdings in AbbVie by 169.3% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 4,722,893 shares of the company’s stock worth $876,662,000 after buying an additional 2,969,202 shares during the last quarter. Finally, Raymond James Financial Inc. boosted its position in shares of AbbVie by 41.8% during the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock worth $1,733,222,000 after acquiring an additional 2,753,312 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Trading Down 1.0%

NYSE:ABBV opened at $224.66 on Friday. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The stock’s 50 day simple moving average is $224.26 and its 200-day simple moving average is $222.71. The firm has a market cap of $397.24 billion, a P/E ratio of 95.19, a PEG ratio of 0.79 and a beta of 0.35.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. AbbVie’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period last year, the firm posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date is Wednesday, April 15th. AbbVie’s payout ratio is 293.22%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. DZ Bank cut AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price for the company. in a research note on Tuesday, November 4th. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. The Goldman Sachs Group restated a “neutral” rating and issued a $223.00 target price on shares of AbbVie in a report on Wednesday, January 28th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Finally, UBS Group reduced their price target on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a research report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.15.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.